peptide research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
There are 21 known isotopes of sodium (11Na), ranging from 17Na to 39Na (except for 36Na and 38Na), and five isomers. 23Na is the only stable (and the only primordial) isotope, making sodium a monoisotopic (and mononuclidic) element. Sodium has two radioactive cosmogenic isotopes (22Na, with a half-life of 2.6019 years and 24Na, with a half-life of 14.956 hours). With the exception of those two isotopes, all other isotopes have half-lives under a minute, most under a second. Acute neutron radiation exposure (e.g., from a nuclear criticality accident) converts some of the stable 23Na in human blood plasma to 24Na. The neutron radiation dose absorbed by the patient can be assessed by measuring the concentration of the radioisotope. 22Na is a positron-emitting isotope with a relatively long half-life, about 2.6 years. It is used to create test-objects and point-sources for positron emission tomography.
=== Available biosimilars === As of 2025, there are three commercially available biosimilar insulins. They are insulin glargine-yfgn, insulin glargine-aglr, and insulin aspart-szjj. Insulin glargine-yfgn is marketed under the name Semglee, and received FDA approval in July 2021, but development began before that. The approval was granted to Mylan, which was merged with another company into Viatris in 2020. The second approved biosimilar insulin, insulin glargine-aglr, was approved by the FDA in December 2021 to be produced by Lilly under the name Rezvoglar. In February 2025, the FDA approved the very first short-acting biosimilar insulin, insulin aspart szjj. It is manufactured by Viatris and sold under the name Merilog. It is of note that although the name of insulin lispro-aabc, which is marketed as Lyumjev by Lilly, is similar to the names of biosimilars, it is not a biosimilar insulin. Insulin lispro-aabc is simply a faster formulation of insulin lispro.
== Pathway == Gluconeogenesis is a pathway consisting of a series of eleven enzyme-catalyzed reactions. The pathway will begin in either the liver or kidney, in the mitochondria or cytoplasm of those cells, this being dependent on the substrate being used. Many of the reactions are the reverse of steps found in glycolysis.
=== Industrial process water === In industrial process, the control of the quality of process water can be critical to the quality of the end product. Water is often used as a carrier of reagents and the loss of reagent to product must be continuously monitored to ensure that correct replacement rate. Parameters measured relate specifically to the process in use and to any of the expected contaminants that may arise as by-products. This may include unwanted organic chemicals appearing in an inorganic chemical process through contamination with oils and greases from machinery. Monitoring the quality of the wastewater discharged from industrial premises is a key factor in controlling and minimizing pollution of the environment. In this application monitoring schemes Analyse for all possible contaminants arising within the process and in addition contaminants that may have particularly adverse impacts on the environment such as cyanide and many organic species such as pesticides. In the nuclear industry analysis focuses on specific isotopes or elements of interest. Where the nuclear industry makes wastewater discharges to rivers which have drinking water abstraction on them, radioisotopes which could potentially be harmful or those with long half-lives such as tritium will form part of the routine monitoring suite.
== In aggregates == Generally, an aggregate has four different moisture conditions. They are Oven-dry (OD), Air-dry (AD), Saturated surface dry (SSD) and damp (or wet). Oven-dry and Saturated surface dry can be achieved by experiments in laboratories, while Air-dry and damp (or wet) are aggregates' common conditions in nature.
Sources: en.wikipedia.org
1867: The Medical and Chirurgical Society of London investigated whether injected narcotics had a general effect (as argued by Hunter) or whether they only worked locally (as argued by Wood). After conducting animal tests and soliciting opinions from the wider medical community, they firmly sided with Hunter. 1894: Luer taper allows two part syringes where the needle and syringe are easily fitted together or separated. 1899: Letitia Mumford Geer patented a syringe which could be operated with one hand and which could be used for self-administered rectal injections. 1946: Chance Brothers in Smethwick, West Midlands, England, produced the first all-glass syringe with interchangeable barrel and plunger, thereby allowing mass-sterilisation of components without the need for matching them. 1949: Australian inventor Charles Rothauser created the world's first plastic, disposable hypodermic syringe at his Adelaide factory. 1951: Rothauser produced the first injection-moulded syringes made of polypropylene, a plastic that can be heat-sterilised. Millions were made for Australian and export markets. 1956: New Zealand pharmacist and inventor Colin Murdoch was granted New Zealand and Australian patents for a disposable plastic syringe.
Neuroendocrine tumors (NETs) are localised clinically using a range of DOTA based radiopharmaceuticals. For PET imaging these are typically Gallium-68 based. A commercial 64Cu-DOTA-TATE product has been FDA approved for localization of somatostatin receptor positive NETs since 2020.
In early September 2024, Little Caesars announced that it would be exiting Singapore, with the last day of operations for the chain being September 30. The last store was in Funan, after the gradual closure of the chain's six other branches throughout the island. In 2022, Little Caesars had plans to expand into France, Germany, and Portugal. In July 2025, Little Caesars expanded to the United Arab Emirates, opening its first branch in Al Barsha, Dubai In May 2026, Little Caesars expanded to Malaysia, opening its first branch in Damansara Utama.
- Spontaneous Protection Enabling Accelerated Response SPEED – (a) Subsistence Preparation by Electronic Energy Diffusion (early military microwave oven) SPIE – (i) originally the Society for Photo-Optical Instrumentation Engineers ("SPIE – The International Society for Optical Engineering" 1981–2007, "SPIE" since 2007) SPL (i) Scottish Premier League Superior Parietal Lobule Sound pressure level SPM – (s) Saint Pierre and Miquelon (ISO 3166 trigram) SPOD – (a/i) Sea Port of Debarkation SPOE – (a/i) Sea Port of Embarkation SPOT – (a) Satellite pour l'observation de la Terre (French, "Satellite for Earth Observation") SPQR – (i) Senatus Populusque Romanus (Latin "The Senate and the People of Rome") sps – (i) sine prole superstite (Latin, "without surviving issue") SPS – (i) Standard Positioning Service (GPS) SPST – (i) Single-Pole Single-Throw
Further extending the shelf-life of stored blood up to 42 days was an anticoagulant preservative, CPDA-1, introduced in 1979, which increased the blood supply and facilitated resource-sharing among blood banks. As of 2006 about 15 million units of blood products were transfused per year in the United States. By 2013 the number had declined to about 11 million units, because of the shift towards laparoscopic surgery and other surgical advances and studies that have shown that many transfusions were unnecessary. For example, the standard of care reduced the amount of blood transfused in one case from 750 to 200 mL. In 2019, 10,852,000 RBC units, 2,243,000 platelet units, and 2,285,000 plasma units were transfused in the United States.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.